Literature DB >> 21686077

Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo.

Srilatha Swami1, Aruna V Krishnan, Jennifer Y Wang, Kristin Jensen, Lihong Peng, Megan A Albertelli, David Feldman.   

Abstract

Calcitriol (1,25-dihydroxyvitamin D(3)), the hormonally active metabolite of vitamin D, exerts many anticancer effects in breast cancer (BCa) cells. We have previously shown using cell culture models that calcitriol acts as a selective aromatase modulator (SAM) and inhibits estrogen synthesis and signaling in BCa cells. We have now examined calcitriol effects in vivo on aromatase expression, estrogen signaling, and tumor growth when used alone and in combination with aromatase inhibitors (AIs). In immunocompromised mice bearing MCF-7 xenografts, increasing doses of calcitriol exhibited significant tumor inhibitory effects (~50% to 70% decrease in tumor volume). At the suboptimal doses tested, anastrozole and letrozole also caused significant tumor shrinkage when used individually. Although the combinations of calcitriol and the AIs caused a statistically significant increase in tumor inhibition in comparison to the single agents, the cooperative interaction between these agents appeared to be minimal at the doses tested. Calcitriol decreased aromatase expression in the xenograft tumors. Importantly, calcitriol also acted as a SAM in the mouse, decreasing aromatase expression in the mammary adipose tissue, while increasing it in bone marrow cells and not altering it in the ovaries and uteri. As a result, calcitriol significantly reduced estrogen levels in the xenograft tumors and surrounding breast adipose tissue. In addition, calcitriol inhibited estrogen signaling by decreasing tumor ERα levels. Changes in tumor gene expression revealed the suppressive effects of calcitriol on inflammatory and growth signaling pathways and demonstrated cooperative interactions between calcitriol and AIs to modulate gene expression. We hypothesize that cumulatively these calcitriol actions would contribute to a beneficial effect when calcitriol is combined with an AI in the treatment of BCa. © Springer Science+Business Media, LLC 2011

Entities:  

Keywords:  Aromatase; Aromatase inhibitors; Breast cancer; Calcitriol; Estrogen synthesis; Selective aromatase modulator; Xenografts

Mesh:

Substances:

Year:  2011        PMID: 21686077      PMCID: PMC3114631          DOI: 10.1007/s12672-011-0073-7

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  62 in total

1.  A novel purification method for multipotential skeletal stem cells.

Authors:  Shousaku Itoh; Jane E Aubin
Journal:  J Cell Biochem       Date:  2009-10-01       Impact factor: 4.429

Review 2.  Application of aromatase inhibitors in endocrine responsive breast cancers.

Authors:  Paul Goss; Melinda Wu
Journal:  Breast       Date:  2007-08-24       Impact factor: 4.380

3.  Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.

Authors:  Yannick Laplante; Claudine Rancourt; Donald Poirier
Journal:  Mol Cell Endocrinol       Date:  2008-09-04       Impact factor: 4.102

4.  Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy.

Authors:  Aruna V Krishnan; Srilatha Swami; Lihong Peng; Jining Wang; Jacqueline Moreno; David Feldman
Journal:  Endocrinology       Date:  2009-11-11       Impact factor: 4.736

Review 5.  Targets of vitamin D receptor signaling in the mammary gland.

Authors:  Joellen Welsh
Journal:  J Bone Miner Res       Date:  2007-12       Impact factor: 6.741

Review 6.  NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.

Authors:  D Craig Allred; Robert W Carlson; Donald A Berry; Harold J Burstein; Stephen B Edge; Lori J Goldstein; Allen Gown; M Elizabeth Hammond; James Dirk Iglehart; Susan Moench; Lori J Pierce; Peter Ravdin; Stuart J Schnitt; Antonio C Wolff
Journal:  J Natl Compr Canc Netw       Date:  2009-09       Impact factor: 11.908

7.  Alternative 5'-untranslated first exons of the mouse Cyp19A1 (aromatase) gene.

Authors:  Jenny D Y Chow; Evan R Simpson; Wah Chin Boon
Journal:  J Steroid Biochem Mol Biol       Date:  2009-04-05       Impact factor: 4.292

8.  Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.

Authors:  C B Confavreux; A Fontana; J P Guastalla; F Munoz; J Brun; P D Delmas
Journal:  Bone       Date:  2007-06-16       Impact factor: 4.398

Review 9.  The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.

Authors:  H S Rugo
Journal:  Ann Oncol       Date:  2007-08-09       Impact factor: 32.976

10.  A novel promoter controls Cyp19a1 gene expression in mouse adipose tissue.

Authors:  Hong Zhao; Joy Innes; David C Brooks; Scott Reierstad; Mehmet B Yilmaz; Zhihong Lin; Serdar E Bulun
Journal:  Reprod Biol Endocrinol       Date:  2009-04-24       Impact factor: 5.211

View more
  24 in total

1.  Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D.

Authors:  Youngtae Jeong; Srilatha Swami; Aruna V Krishnan; Jasmaine D Williams; Shanique Martin; Ronald L Horst; Megan A Albertelli; Brian J Feldman; David Feldman; Maximilian Diehn
Journal:  Mol Cancer Ther       Date:  2015-05-01       Impact factor: 6.261

Review 2.  The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer.

Authors:  Aruna V Krishnan; Srilatha Swami; David Feldman
Journal:  Steroids       Date:  2012-07-16       Impact factor: 2.668

Review 3.  Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: importance of mammary CYP27B1 for treatment and prevention.

Authors:  Aruna V Krishnan; Srilatha Swami; David Feldman
Journal:  J Steroid Biochem Mol Biol       Date:  2012-08-23       Impact factor: 4.292

Review 4.  Breast cancer proteome takes more than two to tango on TRAIL: beat them at their own game.

Authors:  Ammad Ahmad Farooqi; Sundas Fayyaz; Muhammad Tahir; Muhammed Javed Iqbal; Shahzad Bhatti
Journal:  J Membr Biol       Date:  2012-08-17       Impact factor: 1.843

5.  Dietary vitamin D₃ and 1,25-dihydroxyvitamin D₃ (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer.

Authors:  Srilatha Swami; Aruna V Krishnan; Jennifer Y Wang; Kristin Jensen; Ronald Horst; Megan A Albertelli; David Feldman
Journal:  Endocrinology       Date:  2012-03-27       Impact factor: 4.736

6.  Calcitriol induces estrogen receptor α expression through direct transcriptional regulation and epigenetic modifications in estrogen receptor-negative breast cancer cells.

Authors:  Nancy Santos-Martínez; Lorenza Díaz; Victor M Ortiz-Ortega; David Ordaz-Rosado; Heriberto Prado-Garcia; Euclides Avila; Fernando Larrea; Rocío García-Becerra
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

7.  Vitamin D mitigates the adverse effects of obesity on breast cancer in mice.

Authors:  Srilatha Swami; Aruna V Krishnan; Jasmaine Williams; Abhishek Aggarwal; Megan A Albertelli; Ronald L Horst; Brian J Feldman; David Feldman
Journal:  Endocr Relat Cancer       Date:  2016-01-27       Impact factor: 5.678

Review 8.  The role of vitamin D in reducing cancer risk and progression.

Authors:  David Feldman; Aruna V Krishnan; Srilatha Swami; Edward Giovannucci; Brian J Feldman
Journal:  Nat Rev Cancer       Date:  2014-04-04       Impact factor: 60.716

9.  Down-regulation of vitamin D receptor in mammospheres: implications for vitamin D resistance in breast cancer and potential for combination therapy.

Authors:  Shehla Pervin; Martin Hewison; Melissa Braga; Lac Tran; Rene Chun; Amer Karam; Gautam Chaudhuri; Keith Norris; Rajan Singh
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  Vitamin D interacts with Esr1 and Igf1 to regulate molecular pathways relevant to Alzheimer's disease.

Authors:  Véréna Landel; Pascal Millet; Kévin Baranger; Béatrice Loriod; François Féron
Journal:  Mol Neurodegener       Date:  2016-03-01       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.